Clinical Trials Data Sleep Topical 
Cannabis Law Report
DECEMBER 27, 2019
Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.
Cannabis Law Report
MAY 10, 2022
Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. of prescriptions were for sleep disorders. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. The Guardian writes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 10, 2022
First academic study of national medicinal cannabis data. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Very few studies have also been done examining cannabis for the treatment of sleep disorders. Here’s the Uni of Sydney press release.
Cannabis Law Report
JULY 8, 2021
The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids.
Cannabis Law Report
OCTOBER 29, 2021
The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .
Greencamp
AUGUST 16, 2018
The ECS plays an important role in managing numerous processes, ranging from sleep, mood, immune functions, metabolism, movement and pain. The researchers surveyed 48 ALS patients (within the PatientsLikeMe community) who were using cannabis to alleviate their symptoms, and then analyzed the data the patients supplied them with.
The Cannigma
JUNE 15, 2021
However, the scientific data on CBG is nowhere near as developed as what we have on CBD. The vast majority of what we know about CBD’s medicinal effects is based on laboratory studies, is far from being properly understood, and lacks solid scientific data on human subjects — aside from epilepsy 5. Sonya Yruel/Drug Policy Alliance).
Expert insights. Personalized for you.
85 
Let's personalize your content